{"id":"NCT02385318","sponsor":"Padagis LLC","briefTitle":"To Compare Safety and Efficacy of Perrigo's Drug Product Compared to an FDA Approved Drug Product in the Treatment of Actinic Keratosis","officialTitle":null,"status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-02","primaryCompletion":"2015-12","completion":"2015-12","firstPosted":"2015-03-11","resultsPosted":"2021-01-22","lastUpdate":"2021-11-02"},"enrollment":519,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Actinic Keratosis"],"interventions":[{"type":"DRUG","name":"Ingenol Mebutate (Perrigo)","otherNames":["Perrigo product"]},{"type":"DRUG","name":"Ingenol Mebutate (Reference)","otherNames":["Reference Listed Drug Product"]},{"type":"DRUG","name":"Placebo gel","otherNames":[]}],"arms":[{"label":"Test Product","type":"EXPERIMENTAL"},{"label":"Reference product","type":"ACTIVE_COMPARATOR"},{"label":"Placebo product","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to compare safety and efficacy of Perrigo's drug product compared to an FDA approved drug product in the treatment of actinic keratosis.","primaryOutcome":{"measure":"Number of Participants With Complete Clearance (Absence) of Actinic Keratosis Lesions as Determined by Visual Inspection of the Investigator","timeFrame":"Day 57","effectByArm":[{"arm":"Test Product","deltaMin":81,"sd":null},{"arm":"Reference Product","deltaMin":76,"sd":null},{"arm":"Placebo Product","deltaMin":10,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":204},"commonTop":["APPLICATION SITE PAIN","APPLICATION SITE Pruritus"]}}